Ki67, CD105 and α-smooth muscle actin expression in disease progression model of oral submucous fibrosis

Q1 Medicine

Journal of Investigative and Clinical Dentistry Pub Date : 2019-07-19 DOI:10.1111/jicd.12443

Amol R. Gadbail, Minal S. Chaudhary, Sachin C. Sarode, Shailesh M. Gondivkar, Lalita Belekar, Mugdha P. Mankar-Gadbail, Ravi Dande, Satyajit A. Tekade, Monal B. Yuwanati, Shankargouda Patil

{"title":"Ki67, CD105 and α-smooth muscle actin expression in disease progression model of oral submucous fibrosis","authors":"Amol R. Gadbail, Minal S. Chaudhary, Sachin C. Sarode, Shailesh M. Gondivkar, Lalita Belekar, Mugdha P. Mankar-Gadbail, Ravi Dande, Satyajit A. Tekade, Monal B. Yuwanati, Shankargouda Patil","doi":"10.1111/jicd.12443","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Aim</h3>\n \n <p>The aim of this study was to investigate the expression of Ki67, CD105 and α-smooth muscle actin (α-SMA) expression in oral submucous fibrosis (OSF) and oral squamous cell carcinoma in the background of OSF (OSCC-SMF).</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>The study was carried out on paraffin-embedded tissues of 30 normal oral mucosa (NOM), 50 OSF cases and 105 OSCC-SMF. The immunohistochemistry was carried out to evaluate the expression of Ki67, CD105 and α-SMA antigen.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Ki67 labelling index (LI), CD105 and α-SMA expression showed increasing trend from NOM, low-risk epithelial dysplasia (LRED), high-risk epithelial dysplasia (HRED), well-differentiated squamous cell carcinoma (WDSCC), moderately differentiated squamous cell carcinoma to poorly differentiated squamous cell carcinoma. However, there was no significant difference of α-SMA expression between HRED and WDSCC. In OSCC-SMF, Ki67 LI, CD105 and α-SMA were significantly higher in advanced clinical TNM stage, metastasis and less than 3 years patient survival as compared with early clinical TNM stage, non-metastasis and 3 years or more patient survival.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>Ki67 LI, α-SMA and CD105 expression alone or together correspond with the disease progression model of SMF. Hence, expression of these markers can be used as a predictive marker of clinical outcome of OSCC-SMF.</p>\n </section>\n </div>","PeriodicalId":16204,"journal":{"name":"Journal of Investigative and Clinical Dentistry","volume":"10 4","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2019-07-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1111/jicd.12443","citationCount":"20","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative and Clinical Dentistry","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/jicd.12443","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 20

Abstract

Aim

The aim of this study was to investigate the expression of Ki67, CD105 and α-smooth muscle actin (α-SMA) expression in oral submucous fibrosis (OSF) and oral squamous cell carcinoma in the background of OSF (OSCC-SMF).

Methods

The study was carried out on paraffin-embedded tissues of 30 normal oral mucosa (NOM), 50 OSF cases and 105 OSCC-SMF. The immunohistochemistry was carried out to evaluate the expression of Ki67, CD105 and α-SMA antigen.

Results

Ki67 labelling index (LI), CD105 and α-SMA expression showed increasing trend from NOM, low-risk epithelial dysplasia (LRED), high-risk epithelial dysplasia (HRED), well-differentiated squamous cell carcinoma (WDSCC), moderately differentiated squamous cell carcinoma to poorly differentiated squamous cell carcinoma. However, there was no significant difference of α-SMA expression between HRED and WDSCC. In OSCC-SMF, Ki67 LI, CD105 and α-SMA were significantly higher in advanced clinical TNM stage, metastasis and less than 3 years patient survival as compared with early clinical TNM stage, non-metastasis and 3 years or more patient survival.

Conclusion

Ki67 LI, α-SMA and CD105 expression alone or together correspond with the disease progression model of SMF. Hence, expression of these markers can be used as a predictive marker of clinical outcome of OSCC-SMF.

查看原文本刊更多论文

Ki67、CD105和α-平滑肌肌动蛋白在口腔黏膜下纤维化疾病进展模型中的表达。

目的探讨Ki67、CD105和α-平滑肌肌动蛋白(α-SMA)在口腔黏膜下纤维化(OSF)和口腔鳞状细胞癌(OSCC-SMF)中的表达情况。方法对30例正常口腔黏膜(NOM)、50例OSF和105例OSCC-SMF的石蜡包埋组织进行研究。免疫组化检测Ki67、CD105和α-SMA抗原的表达。结果ski67标记指数(LI)、CD105和α-SMA的表达从NOM、低危上皮异常增生(LRED)、高危上皮异常增生(HRED)、高分化鳞状细胞癌(WDSCC)、中分化鳞状细胞癌到低分化鳞状细胞癌均呈升高趋势。而α-SMA在HRED和WDSCC间的表达无显著差异。在OSCC-SMF中，Ki67 LI、CD105和α-SMA在临床TNM晚期、转移期和3年以下患者中的表达明显高于临床TNM早期、无转移期和3年及以上患者。结论ki67li、α-SMA和CD105单独或共同表达符合SMF的疾病进展模型。因此，这些标志物的表达可作为OSCC-SMF临床预后的预测指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Journal of Investigative and Clinical Dentistry DENTISTRY, ORAL SURGERY & MEDICINE-

CiteScore

3.90

自引率

0.00%

发文量

期刊介绍： Journal of Investigative and Clinical Dentistry (JICD) aims to publish quality, peer reviewed original research and topical reviews on all aspects of investigative and clinical dentistry and craniofacial research, including molecular studies related to oral health and disease. Although international in outlook, the Editor especially encourages papers from the Asia Pacific. The journal also aims to provide clinicians, scientists and students of dentistry with a knowledge transfer platform for rapid publication of reports through an international journal, which will be available free online until 2012. Its scope, therefore, is broad, inclusive and international, but with a particular focus on Asia Pacific. The Editor welcomes manuscripts in the following key thematic areas in oral and maxillofacial sciences: Community Dentistry and Oral Epidemiology, Conservative Dentistry, Dental Biomaterials, Dental Pedagogy, Endodontics and Traumatology, Implant Dentistry, Oral Biosciences, Oral and Maxillofacial Surgery, Oral Medicine, Oral Pathology and Oral Microbiology, Orthodontics, Oral Radiology, Oral Rehabilitation, Paedodontics, Periodontology and Periodontal Medicine.